Duality Advisers’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-26,094
Closed -$1.06M 232
2024
Q1
$1.06M Sell
26,094
-26,832
-51% -$1.01M 0.1% 309
2023
Q4
$1.96M Buy
52,926
+12,521
+31% +$472K 0.21% 176
2023
Q3
$1.54M Buy
40,405
+25,021
+163% +$1.02M 0.19% 204
2023
Q2
$555K Sell
15,384
-53,909
-78% -$1.84M 0.07% 376
2023
Q1
$2.65M Buy
69,293
+31,807
+85% +$1.49M 0.3% 126
2022
Q4
$2.13M Buy
+37,486
New +$1.92M 0.24% 139
2022
Q2
Sell
-12,113
Closed -$483K 701
2022
Q1
$483K Buy
+12,113
New +$431K 0.05% 476
2021
Q4
Sell
-90,705
Closed -$3.69M 580
2021
Q3
$3.69M Buy
+90,705
New +$3.79M 0.28% 137
2021
Q2
Sell
-19,907
Closed -$830K 614
2021
Q1
$830K Buy
+19,907
New +$909K 0.07% 375
2020
Q4
Sell
-40,490
Closed -$1.06M 625
2020
Q3
$1.06M Buy
40,490
+7,412
+22% +$206K 0.07% 355
2020
Q2
$887K Buy
+33,078
New +$746K 0.08% 262
2020
Q1
Sell
-22,335
Closed -$396K 142
2019
Q4
$396K Buy
+22,335
New +$387K 0.02% 335

Other funds holding HALO

Duality Advisers's HALO Position: Q2 2024 in Review

Duality Advisers sold out of Halozyme (HALO) in Q2 2024, closing a stake of 26,094 shares — an estimated $1.06M sold.

Duality Advisers first reported a position in HALO in Q4 2019 and held it in 12 quarters. The position peaked at $3.69M in Q3 2021. 460 funds tracked by Wall St. Rank hold HALO as of Q2 2024.

  • Duality Advisers reported no remaining Halozyme position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 26,094 Halozyme shares in Q2 2024, an estimated $1.06M.
  • Duality Advisers first reported a position in Halozyme in Q4 2019 and held it in 12 quarters.
  • Duality Advisers's Halozyme position peaked at $3.69M in Q3 2021.
  • 460 funds tracked by Wall St. Rank held Halozyme as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.